

1 **New insights into *Cryptococcus* extracellular vesicles suggest a new**
2 **structural model and an antifungal vaccine strategy**

3
4 Juliana RIZZO^{1#}, Sarah Sze Wah WONG², Anastasia D. GAZI³, Frédérique MOYRAND^{1#},
5 Thibault CHAZE⁴, Pierre-Henri COMMERE⁵, Sophie NOVAULT⁵, Mariette MATONDO⁴,
6 Gerard PEHAU-ARNAUDET³, Flavia C. G. REIS^{6,7#}, Matthijn VOS⁸, Lysangela R ALVES^{6#},
7 Robin C. MAY^{9#}, Leonardo NIMRICHTER^{10#}, Marcio L. RODRIGUES^{6,10#}, Vishukumar
8 AIMANIANDA² and Guilhem JANBON^{1#*}

9
10 ¹ Unité Biologie des ARN des Pathogènes Fongiques, Département de Mycologie, Institut Pasteur, F-
11 75015, Paris, France

12 ² Unité Mycologie Moléculaire, CNRS UMR2000, Département de Mycologie, Institut Pasteur, F-
13 75015, Paris, France

14 ³ Ultrastructural Bio-Imaging, UTechS UBI, Département de Biologie cellulaire et infection, UMR
15 3528 CNRS, Institut Pasteur, F-75015, Paris, France

16 ⁴ Plateforme Protéomique, Unité de Spectrométrie de Masse pour la Biologie (MSBio), Centre de
17 Ressources et Recherches Technologiques (C2RT), UMR 2000 CNRS, Institut Pasteur, Paris, France

18 ⁵ Cytometry and Biomarkers, Centre de Ressources et Recherches Technologiques (C2RT), Institut
19 Pasteur, F-75015, Paris, France

20 ⁶ Instituto Carlos Chagas, Fundação Oswaldo Cruz (FIOCRUZ), Curitiba, Brazil

21 ⁷ Centro de Desenvolvimento Tecnológico em Saúde (CDTS-Fiocruz), Brazil

22 ⁸ NanoImaging Core Facility, Centre de Ressources et Recherches Technologiques (C2RT), Institut
23 Pasteur, F-75015, Paris, France

24 ⁹ Institute of Microbiology and Infection and School of Biosciences, University of Birmingham,
25 Birmingham B15 2TT, United Kingdom

26 ¹⁰ Instituto de Microbiologia Paulo de Góes (IMPG), Universidade Federal do Rio de Janeiro, Rio de
27 Janeiro, Brazil

28
29 # Members of the data sharing transparency group on fungal extracellular vesicles

30 * Corresponding author: janbon@pasteur.fr

31

32

33

34 **Abstract**

35

36 Whereas extracellular vesicle (EV) research has become commonplace in different biomedical
37 fields, this field of research is still in its infancy in mycology. Here we provide a robust set of
38 data regarding the structural and compositional aspects of EVs from the pathogenic yeast *C.*
39 *neoformans*. By using cutting-edge methodological approaches including cryogenic electron
40 microscopy and cryogenic electron tomography, proteomics, and nanoscale flow cytometry, we
41 revisited cryptococcal EV features and suggest a new EV structural model, in which the
42 vesicular lipid bilayer is covered by a 16 nm thick mannoprotein-based fibrillar decoration,
43 bearing the capsule polysaccharide as its outer layer. About 10% of the EV population is devoid
44 of fibrillar decoration, adding another aspect to EV diversity. By analyzing EV protein cargo
45 from three cryptococcal species, we characterized the typical *Cryptococcus* EV proteome. It
46 contains several membrane-bound protein families, including some Tsh proteins bearing a
47 SUR7/PalI motif. The presence of known protective antigens on the surface of *Cryptococcus*
48 EVs, resembling the morphology of encapsulated virus structures, suggested their potential as
49 a vaccine. Indeed, mice immunized with EVs obtained from an acapsular *C. neoformans* mutant
50 strain rendered a strong antibody response and significantly prolonged survival of mice upon
51 *C. neoformans* infection.

52

53 Keywords: *Cryptococcus*, fungal infections, extracellular vesicles, mannoproteins, vaccine;
54 Cryo-EM

55

56

57

58

59 1. Introduction

60 All living organisms release lipid bilayer-delimited particles defined as extracellular
61 vesicles (EVs) (Deatherage and Cookson 2012, Witwer and Théry 2019). EV sizes range from
62 20 nm to close to one micrometer in diameter. In mammalian cells, two major classes of EVs
63 have been defined, microvesicles and exosomes, according to their size and cellular origin
64 (Meldolesi 2018, van Niel et al. 2018). In these organisms, a large body of literature describes
65 how EVs participate in intercellular signaling within an organism but also in organism-to-
66 organism communication, including carcinogenesis and host-pathogen interactions (Xu et al.
67 2018, Shopova et al. 2020). In fungi, the first report of fungal EVs was published in 2007
68 (Rodrigues et al. 2007), and, since then, their existence has been reported in many species of
69 pathogenic and nonpathogenic fungi (Rizzo et al. 2020).

70 By analogy with mammalian EVs, it has been hypothesized that fungal EVs could also
71 participate in many biological processes (Rodrigues and Casadevall 2018). Indeed, some
72 reports indicate their relevance in diverse mechanisms related to fungal pathophysiology, such
73 as antifungal resistance and biofilm formation (Leone et al. 2018, Zarnowski et al. 2018),
74 transfer of virulence-associated molecules and modulation of host cells (Oliveira et al. 2010,
75 Vargas et al. 2015, Rizzo et al. 2017, Bielska et al. 2018, Souza et al. 2019, Hai et al. 2020),
76 cell wall remodeling and biogenesis (Zhao et al. 2019, Rizzo et al. 2020), among others (Bielska
77 and May 2019, Rizzo et al. 2020). Nevertheless, the molecular mechanisms implicated in these
78 exchanges of information, as well as the genetics regulating fungal EV biogenesis and release,
79 remain elusive.

80 As with their mammalian, bacterial and plant counterparts, fungal EVs have been shown
81 to contain proteins, pigments, nucleic acids, polysaccharides, lipids, among other molecules
82 (Eisenman et al. 2009, Vallejo et al. 2012, da Silva et al. 2015, Rodrigues et al. 2015, Joffe et
83 al. 2016, Rayner et al. 2017). Besides the claudin-like Sur7 family proteins, recently suggested
84 as EV protein markers in *Candida albicans* (Dawson et al. 2020), no other fungal EV specific
85 molecular marker has been reported. Indeed, the laborious and inefficient EV isolation
86 protocols that have been used until recently have strongly limited the knowledge on their
87 composition. Additional hurdles regarding purification methods can possibly affect an accurate
88 vesicular compositional characterization (Théry et al. 2018), including potential carryover
89 contaminants such as protein aggregates (Chiou et al. 2018). Regarding EV morphological
90 diversity, previous studies have reported the heterogeneity of fungal EV size, as recently
91 reviewed (Bielska and May 2019). However, single particle analyzers such as the widely used
92 Nanoparticle Tracking Analysis (NTA) and most common flow cytometers cannot reliably

93 evaluate particles smaller than 100 nm in diameter (Maas et al. 2015, Théry et al. 2018, Chiang
94 and Chen 2019, Noble et al. 2020). Overall, although a considerable number of fungal EV-
95 related studies have been published in recent years, our knowledge of fungal EV structure and
96 composition remains limited, which prevents further robust analysis of their functions.

97 *C. neoformans* is a major fungal pathogen, affecting mostly immunocompromised
98 patients (Rajasingham et al. 2017) and has historically been the one of the most studied fungi
99 regarding EV biology (Rodrigues et al. 2007, Bielska and May 2019, Rizzo et al. 2020).
100 However, the only structural analyses of EVs from this organism are now very outdated and
101 technologies used have shown tremendous improvements since then (Emelyanov et al. 2020,
102 Noble et al. 2020). Additionally, so far *Cryptococcus* EV proteomics identified only 92 and 202
103 proteins, with very poor overlap and no evaluation of their abundance or enrichment (Rodrigues
104 et al. 2008, Wolf et al. 2014). Finally, although the current model of fungal EV structure
105 contains proteins located on the vesicular surface (by analogy with the mammalian EV
106 structures (Emelyanov et al. 2020, Noble et al. 2020)), more experimental evidence is necessary
107 to identify these putative membrane-associated molecules in fungal EVs.

108 Since many immunogenic proteins are often found to be associated with EVs, their
109 vaccine potential has been explored mostly for bacterial and parasitic infections (Coakley et al.
110 2017, Wang et al. 2018), and more recently also for fungal infections (Colombo et al. 2019,
111 Vargas et al. 2020). In the present study, we used the recently described protocol (Reis et al.
112 2019), to obtain EV- enriched samples from *Cryptococcus* cells, together with cutting edge
113 methodological approaches to revisit *Cryptococcus* EV structure, cargo, and biological
114 functions. We produced a robust set of data containing cryo-electron microscopy (cryo-EM)
115 and cryo-electron tomography (cryo-ET) proteomics, and nanoscale flow cytometry analysis,
116 suggesting a new EV structural model, in addition to a list of cryptococcal EV protein markers.
117 Our results led us to evaluate the EV biological roles in mice models further, emphasizing their
118 potential use as an anti-cryptococcosis vaccine.

119

120 **2. Material and Methods**

121

122 **Strains and media**

123 The wild type strains used in the study were *C. neoformans* strain KN99 α , *C. deneoformans*
124 strain JEC21, *C. deuterogattii* strain R265, *C. albicans* strain SC5314, and *S. cerevisiae* strain
125 S288C. To construct the strains NE1281 and NE1282 (*MAT α mp88 Δ ::NEO*) the entire

126 CNAG_03223 CDS was replaced by the NEO marker in KN99 α following the previously
127 described CRISPR CAS9 method (Fan and Lin 2018). The plasmid pPZP-NEO1 used to
128 amplify the *NEO* selective marker was kindly provided by Dr. Joseph Heitman (Duke
129 University). The deletion cassettes as constructed using a strategy previously applied to
130 *Neurospora crassa* (Collopy et al. 2010). The transformants were then screened for homologous
131 integration, as previously described (Moyrand et al. 2007). Two representatives independently
132 obtained mutant strains were stocked at -80°C. All primer sequences used are provided in Table
133 S3. The *vep1A::NAT* (CNAG_03223) has been constructed Hiten Madhani lab (UCSF, USA)
134 obtained from the Fungal Genetic stock center. All strains were taken from the G. Janbon
135 laboratory collection at -80°C, plated on yeast extract-peptone-dextrose (YPD) and incubated
136 at 30°C for 48h before each experiment.

137

138 **EV isolation and labeling**

139 EV purification was based on the recently published protocol (Reis et al. 2019) with
140 some modifications. One loop of cells was inoculated into 10 mL of liquid YPD and incubated
141 at 30°C for 24h with shaking (150rpm). Cells were washed two times with 10 ml of sterile
142 water, counted and diluted to a density of 3.5×10^7 cells/mL in water. Aliquots of 300 μ L of the
143 cellular suspension were spread onto synthetic dextrose (SD) solid medium plates and incubated
144 for 24h at 30°C to reach cell confluence. The cells were recovered from each plate with a 10 μ L
145 inoculation loop and transferred to an ultracentrifugation tube containing 10 mL 0.22 μ m-filter
146 sterile PBS 0.01M. Cells were homogenized and collected by centrifugation at 5,000 x g for 15
147 min at 4°C. Supernatants were collected and centrifuged again at 15,000 x g for 15 min at 4°C
148 to eliminate cellular debris. The resting supernatants were filtered at 0.45 μ m syringe filters and
149 ultracentrifuged at 100.000 x g for 1h at 4°C (SW 41 Ti swinging-bucket rotor, Beckman
150 Coulter). The supernatant was discarded and pellets suspended in 0.22 μ m-pore filtered or 0.02
151 μ m-pore filtered (in case of Flow Cytometry analysis) PBS for immediately use, or stored at -
152 80°C for further experiments.

153 EVs were obtained as previously described and finally suspended in 100 μ L of 0.02 μ m-
154 pore filtered PBS. EVs were labeled either with the Concanavalin A (ConA) - Alexa Fluor™
155 488 conjugated, or with the Alexa 488 labeled anti-GXM monoclonal antibody 18B7
156 (Casadevall et al. 1992), a kind gift of Oscar Zaragoza. The ConA stock solution (5mg/mL)
157 was previously centrifuged at 13.000 x rpm for 2 min, in order to eliminate possible aggregates,
158 and diluted to 500 μ g/mL in filtered PBS. In 1.5 mL Eppendorf tubes, 5 μ L of ConA (500
159 μ g/mL), together with 5 μ L EV suspension were add to a final volume of 200 μ L filtered PBS.

160 The tubes were incubated for one hour at 30°C, under agitation and protected from light. After
161 incubation, 200 µL of 0.02 µm-pore filtered PBS were added to each tube and 300 µL of the
162 final suspension was transferred to BD Trucount™ Tubes (BD Biosciences) and proceeded to
163 Flow Cytometry analysis. Similar protocol was applied for the EV labeling with the Alexa 488
164 labeled anti-GXM monoclonal antibody 18B7, which was diluted 20 times before adding to EV
165 suspension.

166

167 **Flow cytometry**

168 EV were analyzed and sorted on a cell sorter MoFlo Astrios (Beckman Coulter)
169 equipped with an EQ module specifically developed to detect nanoparticles and with 488 nm
170 and 561 nm lasers at 200 mW. The sorting was carried out with a 70 µm nozzle at a pressure of
171 60 PSI and a differential pressure with the sample of 0.3-0.4 PSI. The sheath liquid NaCl 0.9%
172 (REVOL, France) was filtered on a 0.04 µm filter. The analyses were on the SSC parameter of
173 laser 561, with threshold set to 0.012% in order to have maximum 300 eps. An M2 mask was
174 added in front of the FSC. All SSC and FSC parameters are viewed in logarithmic mode. The
175 calibration of the machine was carried out using Megamix-Plus SSC beads from BioCytex. We
176 used the Trucount™ Tubes to normalize the EV counting for ConA labeling, and the
177 fluorescence of the Mab18B7 and alexa 488 conjugated, and beads Trucount™ was measured
178 on parameter 488-513/26.

179

180 **Nanoparticle tracking analysis (NTA)**

181 Quantitative determination of EV size distribution was performed by NTA, in addition
182 to microscopic methods. Protocols that were recently established for analysis of cryptococcal
183 vesicles were used (ref Reis 2019, already in the reference list). Briefly, ultracentrifugation
184 pellets were 20- to 50-fold diluted in filtered PBS and measured within the optimal dilution
185 range of 9×10^7 to 2.9×10^9 particles/ml on an LM10 nanoparticle analysis system, coupled
186 with a 488-nm laser and equipped with an SCMOS camera and a syringe pump (Malvern
187 Panalytical, Malvern, United Kingdom). The data were acquired and analyzed using the NTA
188 3.0 software (Malvern Panalytical).

189

190 **Cryo-EM and cryo-ET**

191 Four microliters of EV samples, obtained from 24 plates of *C. neoformans* WT, were
192 spotted on glow-discharged lacey grids (S166-3, EMS). The samples were cryo-fixed by plunge
193 freezing at -180°C in liquid ethane using a Leica EMGP (Leica, Austria). Grids were observed

194 either with Tecnai F20, or Titan Krios (Thermo Fisher Scientific). The Tecnai F20 (Thermo
195 Fisher Scientific) was operating at 200kV and images were acquired under low-dose conditions
196 using the software EPU (Thermo Fisher Scientific) and a direct detector Falcon II (Thermo
197 Fisher Scientific).

198 Cryo electron tomography was performed using 5 nm protein A gold particles (UMC,
199 Utrecht). These were mixed with the sample to serve as fiducial markers for subsequent image
200 alignment. 4 μ l of sample was applied to glow discharged Lacey grids (S166-3, EMS) prior
201 plunge-freezing (EMGP, Leica). Initial bi-directional tilt series acquired using a TECNAI F20
202 transmission electron microscope (FEI) operated at 200kV under parallel beam conditions using
203 a Gatan 626 side entry cryoholder. The SerialEM software (Mastronarde 2005, Schorb et al.
204 2019) was used to automatically acquire images every 2° over a $\pm 45^\circ$ range using a Falcon II
205 direct detector with a pixel size of 2 \AA , using a total dose of 180 electrons per \AA^2 .

206 Dose-symmetric tilt series were collected on a 300kV Titan Krios (Thermo Scientific)
207 transmission electron microscope equipped with a Quantum LS imaging filter (Gatan, slit with
208 20 eV), single-tilt axis holder and K3 direct electron detector (Gatan). Tilt series with an angular
209 increment of 2° and an angular range of $\pm 60^\circ$ were acquired with the Tomography software
210 (Thermo Scientific). The total electron dose was between 120 and 150 electrons per \AA^2 and the
211 pixel size at 3.38 \AA . Dose symmetric tilt series were saved as separate stacks of frames and
212 subsequently motion-corrected and re-stacked from -60° to $+60^\circ$ using IMOD's function align
213 frames (Mastronarde and Held 2017) with the help of a homemade bash script.

214 Initial image shifts were estimated using IMOD's function tiltcorr. Alignments were
215 further optimized in IMOD using the tracing of 30-40 gold fiducials across the tilt series. The
216 fiducial models gave an overall of a fiducial error around $6 \pm 2.7 \text{\AA}$. In cases of a higher error,
217 local alignments were taken into consideration, to further correct the sample's beam induced
218 motion observed. Three-dimensional reconstructions were calculated in IMOD by weighted
219 back projection using the SIRT-like radial filter to enhance contrast and facilitate subsequent
220 segmentation analysis.

221

222 **EV modeling and analysis of tomographic data**

223 Tomograms were displayed and analyzed using the 3dmod interface of IMOD (Kremer
224 et al. 1996). The vesicles were modeled with manual tracing of their great circle prior the use
225 of the spherical interpolator of IMOD. If the elliptical contours calculated, could not follow
226 adequately the vesicular membrane, further manual tracing was used before re-applying the
227 interpolator. This involved tracing of membranes near the poles of the vesicles where the

228 membrane information could still be followed. To evaluate and assign diameters to a total of
229 434 regular vesicles, located in 39 tomograms, the value of the perimeter of the spheroid's great
230 circle was extracted using the imodinfo function of IMOD, from the same initial manually
231 traced contours used for modelling. To display in 3D the vesicle contour data were meshed
232 using the imodmesh function of IMOD. The projections of the 3D spheroidal models were
233 displayed and rotated to study their 3D geometry.

234 For the evaluation of the decoration thickness, 105 regular vesicles were analyzed by
235 manually measuring the outer EV diameter (delimited by the fibrillar decoration) and the inner
236 diameter (delimited by the lipid bilayer), across the longest axis of the vesicle. The final
237 calculation of the decoration thickness was the subtraction of the inner diameter from the outer
238 diameter, divided by two. For the modeling of the fibrillar decoration, the IMOD surface models
239 were imported to UCSF Chimera (Pettersen et al. 2004). The models were used as masks to
240 extract a slab of data around their outer surface, corresponding to the decoration. The thickness
241 of the slab used refers to the mean value provided by the aforementioned manual analysis. Iso-
242 surface representation of the decoration and final 3D data visualization of the models performed
243 with UCSF Chimera (Pettersen et al. 2004).

244

245 **Immunization assays**

246 The animal experiments were approved by the ethical committee for animal experimentation
247 Comité d'Éthique en Experimentation Animale (CETEA Project license number 2013-0055).
248 Six-week old female BALB/C mice (Janvier Labs) were used in the two sets of vaccination
249 assays. Three successive intraperitoneal injections (using either 1 or 10 µg of EVs-associated
250 proteins in 100 µL) of 14-day intervals were given to the mice. Control group of mice was
251 injected only with PBS. Blood was collected three-eleven days after the last immunization and
252 tested for antibody response by Western blot. Briefly, the EVs-associated proteins were
253 separated on 12% SDS-PAGE, and electroblotted to nitrocellulose membrane. By Western
254 blotting, using the mouse sera at dilution 1:1000 and anti-mouse IgG antibody peroxidase
255 conjugated (Sigma Aldrich), the antibody response specific to the EV-associated proteins was
256 examined. Once the antibody response has been confirmed, all the immunized and control mice
257 were challenged intranasally, around one month from the last immunization, with 10^4 cells of
258 a wild-type *C. neoformans*, and the body weights and survival were monitored.

259

260 **Vesicle denaturation and protein digestion**

261 Protein samples were solubilized in urea 8 M, Tris 100 mM pH7.5, 5 mM tris (2-carboxyethyl)
262 phosphine (TCEP) for 20 min at 23°C. Samples were sonicated using a Vibracell 75186 and a
263 miniprobe 2 mm (Amp 80% // Pulse 10 off 0.8, 3 cycles). Proteins were then alkylated with 20
264 mM iodoacetamide for 30 min at room temperature in the dark. Subsequently, LysC (Promega)
265 was added for the first digestion step (protein to Lys-C ratio = 80:1) for 3h at 30°C. Then
266 samples were diluted down to 1 M urea with 100 mM Tris pH 7.5, and trypsin (Promega) was
267 added to the sample at a ratio of 50:1 for 16h at 37°C. Proteolysis was stopped by adding Formic
268 acid (FA) to a final concentration of 1 % (vol/vol). Resulting peptides were desalted using Sep-
269 Pak SPE cartridge (Waters) according to manufactures instructions.

270

271 **LC-MS/MS of tryptic digest**

272 LC-MS/SM analysis of digested peptides was performed on an Orbitrap Q Exactive Plus mass
273 spectrometer (Thermo Fisher Scientific, Bremen) coupled to an EASY-nLC 1200 (Thermo
274 Fisher Scientific). A home-made column was used for peptide separation (C₁₈ 40 cm capillary
275 column picotip silica emitter tip (75 µm diameter filled with 1.9 µm Reprosil-Pur Basic C₁₈-
276 HD resin, (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany)). It was equilibrated and
277 peptide was loaded in solvent A (0.1 % FA) at 900 bars. Peptides were separated at 250 nl.min⁻¹
278 ¹. Peptides were eluted using a gradient of solvent B (ACN, 0.1 % FA) from 3% to 22% in 160
279 min, 22% to 50% in 70 min, 50% to 90% in 5 min (total length of the chromatographic run was
280 250 min including high ACN level step and column regeneration). Mass spectra were acquired
281 in data-dependent acquisition mode with the XCalibur 2.2 software (Thermo Fisher Scientific,
282 Bremen) with automatic switching between MS and MS/MS scans using a top-10 method. MS
283 spectra were acquired at a resolution of 70000 (at *m/z* 400) with a target value of 3 × 10⁶ ions.
284 The scan range was limited from 300 to 1700 *m/z*. Peptide fragmentation was performed using
285 higher-energy collision dissociation (HCD) with the energy set at 27 NCE. Intensity threshold
286 for ions selection was set at 1 × 10⁶ ions with charge exclusion of *z* = 1 and *z* > 7. The MS/MS
287 spectra were acquired at a resolution of 17500 (at *m/z* 400). Isolation window was set at 1.6 Th.
288 Dynamic exclusion was employed within 45s.

289

290 **Data processing**

291 Data were searched using MaxQuant (version 1.5.3.8 and 1.6.6.0) (Cox and Mann 2008,
292 Tyanova et al. 2016) using the Andromeda search engine (Cox et al. 2011) against home-made
293 databases. The following databases were used. For *C. neoformans* KN99α, *C. deneoformans*
294 JEC21 and *C. deuterogattii* R265 we used the recently updated proteomes (Ferrareze et al.

295 2020, Wallace et al. 2020). The following search parameters were applied:
296 carbamidomethylation of cysteines was set as a fixed modification, oxidation of methionine
297 and protein N-terminal acetylation were set as variable modifications. The mass tolerances in
298 MS and MS/MS were set to 5 ppm and 20 ppm respectively. Maximum peptide charge was set
299 to 7 and 7 amino acids were required as minimum peptide length. A false discovery rate of 1%
300 was set up for both protein and peptide levels. The iBAQ intensity was used to estimate the
301 protein abundance within a sample (Schwanhäusser et al. 2011).

302

303 **Statistical analysis**

304 All statistical analyses were performed using GraphPad Prism 8 software (GraphPad Software
305 Inc.). Data sets were tested for normal distribution using Shapiro-Wilk or Kolmogorov-Smirnov
306 normality tests. In the cases in which the data passed the normality test, they were further
307 analyzed using the unpaired Student's t test. When at least one data set was nonnormally
308 distributed, we used the nonparametric Kolmogorov-Smirnov test. For the comparison of the
309 survival curves, we used the Logrank (Mantel-Cox) test.

310

311

312 **3. Results**

313

314 - *Diversity of EVs produced by Cryptococcus*

315

316 Several groups have already performed morphological studies of fungal EVs by electron
317 microscopy (Rodrigues et al. 2007, Oliveira et al. 2009, Rayner et al. 2017, Bleackley et al.
318 2020). However, most of these previous fungal EV structural analysis used sample fixation and
319 dehydration procedures for transmission electron microscopy (TEM), which can often affect
320 the size and morphology of EVs (Van Der Pol et al. 2010, Chiang and Chen 2019). Cryo-EM
321 imaging on rapid freezing samples at low temperature could potentially reduce sample
322 damaging and artifacts caused by the addition of heavy metals, dehydration, or fixation steps
323 (Orlov et al. 2017, Chiang and Chen 2019). Indeed, diverse morphologies of EVs derived from
324 even a single mammalian cell type have been clearly revealed under cryo-EM (Zabeo et al.
325 2017). We therefore used cryo-EM and cryo-ET in an effort to analyze EVs purified from *C.*
326 *neoformans* cells, in their near-native state.

327 Based on the optimized version of the EV purification protocol recently described by
328 Reis and collaborators (Reis et al. 2019), we isolated EVs from *C. neoformans* reference strain

329 KN99 α , cultured on synthetic dextrose solid medium for 24h, in order to limit the carryover of
330 potential contaminants. Cryo-ET tomograms allowed us to analyze 533 single vesicles, which
331 were characterized according to their morphological aspects in regular (round-bilayered
332 vesicles) and irregular (not rounded – bilayered or multilayered vesicles) categories. Although
333 a large proportion (81.4%) of the observed EVs had the typical round shape, 18.6%
334 corresponded to irregular morphologies. Among them, we observed examples of multilayer
335 vesicles (1.7%), long tubular (2.3%), flat (4.7%), short tubular (6.9%), and miscellaneous
336 morphologies (3.0%). The EV morphological diversity and distribution percentage in each
337 subcategory are explored in **Fig. 1**.

338 Cryo-EM analysis showed a considerable polymorphism of EVs, with the two leaflets
339 of the typical vesicular membrane readily visible for all EVs observed, and a few unstructured
340 aggregates, thus confirming the quality of our preparation (**Fig. 2A**). Among the regular
341 vesicles, only 10.8% appeared to have a smooth surface (**Fig. 2B and 2C**); the majority of
342 regular EVs (89.2%) were decorated with a fibrillar structure anchored to the lipid bilayer (**Fig.**
343 **2D and 2E**). Strikingly, regardless of the morphology, the majority of EVs analyzed (88.6%)
344 appeared to be coated with this fibrillar material. We used the cryo-ET to prepare a three-
345 dimensional surface model of the EVs, using the IMOD (Mastronarde and Held 2017) and
346 UCSF Chimera (Pettersen et al. 2004) to further visualize their structure and fibrillar decoration
347 (**Fig. 2F to 2H**).

348 Additional aspects of *C. neoformans* EV diversity, such as the distribution of size and
349 decoration, were analyzed. NTA analyses showed a diameter size distribution from 80 to 500
350 nm and revealed a major peak of vesicle detection in the 150-nm-diameter range (**Fig. 3A**), in
351 line with previous findings (Reis et al. 2019). We also analyzed the EV diameter frequency
352 distribution by cryo-EM from the 434-single regular EV captures (**Fig. 3B**). The size
353 distribution of vesicles tracked with NTA was different from the distribution of vesicles
354 observed with cryo-EM, which revealed a wider range of EV diameter size, ranging from as
355 small as 10 nm to 500 nm (**Fig. 3C**). Notably, smaller vesicles (< 100 nm) comprised a higher
356 proportion of vesicles captured by cryo-EM than NTA. Although cryo-EM has some statistical
357 limitations, it nonetheless confirms the known bias of NTA towards larger EVs (Bachurski et
358 al. 2019).

359 Analysis of the EV size according to the presence or absence of the surface decoration
360 revealed a different frequency distribution (**Fig. 3D**), with non-decorated EVs showing a
361 significantly smaller size distribution ($p=0.01$, using the nonparametric Kolmogorov-Smirnov
362 test) compared to the decorated ones (**Fig. 3E**). Additionally, the analysis of the vesicular

363 decoration in 105 single regular EVs revealed heterogeneity in their thickness, ranging from 5
364 to 23 nm with the average value close to 16 nm (**Fig. 3F**). There was no correlation between
365 vesicular diameter size and decoration thickness, as indicated by linear regression analysis (**Fig.**
366 **3G**). Therefore, the presence or absence of decoration, and even its thickness, does not depend
367 on the size and shape of the EVs, revealing a previously unknown aspect of fungal EV diversity.

368 369 - *Cryptococcus EV structure analysis*

370 *C. neoformans* is an encapsulated microorganism, and its capsule is mostly composed
371 of the polysaccharide named glucuronoxylomannan (GXM), a critical virulence factor of this
372 pathogenic yeast (O'Meara and Alspaugh 2012). GXM has been previously shown to be
373 exported by EVs (Rodrigues et al. 2007). Therefore, we reasoned that the fibrillar decoration
374 observed around the vesicles could be composed of this capsular polysaccharide. We thus
375 incubated *C. neoformans* EVs with the Alexa 488 labeled anti-GXM monoclonal antibody
376 18B7 (Casadevall et al. 1992), and analyzed the EV suspension was by flow cytometry. More
377 than 70% of the EVs obtained from the wild-type strain were recognized by this antibody (**Fig.**
378 **4A**), suggesting that most *C. neoformans* EVs are covered to some extent with GXM or
379 derivatives thereof. While, EVs obtained from the acapsular mutant strain (*cap59Δ*) (Moyrand
380 et al. 2007) were weakly labeled (2.33%), using the same experimental approach (**Fig. 4B**).
381 Nevertheless, cryo-EM observation of *cap59Δ* EVs revealed similar fibrils as observed in the
382 wild type EVs (**Fig. 4B**). Moreover, cryo-EM analysis of EVs purified from *cap59Δ* suggested
383 a similar percentage of decorated EVs (91.6%). Overall, these data suggest that, even though
384 GXM covers most *C. neoformans* EVs, the visible fibrillar structures around them are not
385 GXM-based. Cryo-EM analysis of EVs obtained from *C. albicans* SC5314 and *S. cerevisiae*
386 S288C grown on SD medium showed a similar fibrillar decoration we observed around
387 *Cryptococcus* EVs (**Fig. 4C**), reinforcing the notion that this structure is not GXM-based, since
388 neither of these two yeasts can synthesize this capsular polysaccharide.

389 We then reasoned that EV decoration might be protein-based and therefore performed
390 proteomic analyses to further explore this novel fungal vesicular feature. Two proteomic
391 analyses of *C. neoformans* EVs have been reported previously (Rodrigues et al. 2008, Wolf et
392 al. 2014) wherein the authors identified 92 and 202 proteins in *C. neoformans* EV extracts,
393 respectively. However, neither quantitative nor enrichment of EV-associated proteins was
394 performed in these two studies. Therefore, we performed EV proteomic characterization,
395 together with an enrichment analysis in order to distinguish the proteins associated with EVs,

396 from the ones related to potential carryover aggregates, inevitably contaminating EV
397 preparations.

398 In fungi, and more specifically in *Cryptococcus*, the relationship between RNA and
399 protein abundances has been reported as nearly linear, due to the relatively minor contribution
400 of posttranscriptional regulations to protein abundance (Wallace et al. 2020). We thus used
401 cellular RNA abundance at 30°C, exponential phase (Wallace et al. 2020), as a proxy for
402 cellular protein abundance, and for normalization of EV proteome data. *C. neoformans* EVs
403 proteomic analysis was performed in experimental triplicate and produced a common list of
404 1847 proteins (**Table S1**).

405 Proteins were ranked according to their prevalence in the sample evaluating the average
406 intensity-based absolute quantification (IBAQ) value of the three replicates. We then used the
407 gene expression level as evaluate by RNA-seq analysis to calculate an enrichment coefficient
408 comparing the expected value in the cells with the observed one in EVs. We thus identified 39
409 non-ribosomal proteins which were present both within the 100 most prevalent EV proteins
410 overall and within the 100 most enriched proteins. We considered these proteins as EV-
411 associated proteins. Only 9 out of these 39 proteins were reported in previous proteomic
412 analysis, emphasizing the necessity for proteomic data enrichment analysis. Of note, our study
413 and those published before used different culture media, and distinct protocols of EV isolation,
414 which might also explain the differences in protein composition that were presently observed.

415 To further explore how conserved EV protein cargo is across *Cryptococcus* species, we
416 proceeded with the same strategy to characterize the EV-associated proteins in two other
417 cryptococcal species, *C. deneoformans* (strain JEC21) and *C. deuterogattii* (strain R265). We
418 identified 38 and 48 EV-associated proteins for *C. deneoformans* and *C. deuterogattii*,
419 respectively (**Table S2**). Overall, 71 EV-associated proteins were identified, 37 in at least two
420 species, and 17 shared by all the three species (**Fig. 5A and B**), supporting a conserved profile
421 of the EV-associated proteins across *Cryptococcus* species, and the robustness of our analyses.

422 Several families of proteins appeared to be typical of *Cryptococcus* EVs. The major one
423 was the Chitin deactylase Cda family (Baker et al. 2011), composed of three members present
424 among the 17 EV-associated proteins identified in all *Cryptococcus* species analyzed. Some
425 other families like the putative glyoxal oxidase (Gox proteins), or the Ricin-type beta-trefoil
426 lectin domain-containing protein (Ril), have one member common to all three species EVs (i.e.
427 Gox2 and Ril1) whereas the other members are found in only two species (Ril2 and Ril3) or are
428 specific of one species EVs (Gox1 and Gox3) (**Fig. 5C**). We also identified three tetraspanin
429 membrane proteins containing a SUR7/PalI family motif. Tsh1 and Tsh2 shared 32% of identity

430 in their amino acid sequence. Tsh1 is present in both *C. neoformans* and *C. deneoformans* EVs
431 whilst Tsh2 was identified in both *C. neoformans* and *C. deuterogattii*. The third Sur7/Pall
432 protein shares very little sequence homology beyond the SUR7 motif and is exclusive to *C.*
433 *deuterogattii*. Two Sur7 proteins have been recently identified in *C. albicans* EVs, suggesting
434 that they might represent a common EV marker present in fungal EVs (Dawson et al. 2020).
435 Finally, two members of the previously described pr4/barwin domain Blp protein family (Chun
436 et al. 2011) were present in *C. neoformans* and *C. deuterogattii* EVs but not in *C. deneoformans*.
437 Similarly, the two ferroxidase Cfo proteins (Jung et al. 2008) were shown to be associated only
438 with the *C. deuterogattii* EVs but not in the two other species.

439 Several enzymes associated with polysaccharide degradation and modifications were
440 present in *Cryptococcus* EVs. Some of these proteins are specific of one species but some others
441 are present in two or all three EV proteomes. For instance, the identification within the
442 *Cryptococcus* EV core proteins of Gas1 (a 1,3-beta-glucanosyltransferase), Amy1 (an alpha
443 amylase), Exg104 (a glucan 1,3-beta-glucosidase), Hep1 (a putative heparinase) together with
444 the Gox, Cda and Ril proteins suggest functions of EVs in cell wall processes, as previously
445 hypothesized in *S. cerevisiae* (Zhao et al. 2019). Finally, several of the EVs proteins identified
446 here have no predicted function; we therefore named them Vep (Vesicles enriched protein).

447 Bioinformatics analysis of the 71 EV-associated protein sequences suggested that 80%
448 might be membrane-bound, 36 of them bearing at least one putative transmembrane domain as
449 predicted by SignalP-5.0 (Almagro Armenteros et al. 2019) and/or TMHMM v. 2.0 (Krogh et
450 al. 2001), and 21 being putative GPI-anchored proteins as predicted by PredGPI (Pierleoni et
451 al. 2008), which is in good agreement with putative protein-based decoration. Reflecting the
452 general specificities of these three proteomes, the GPI-anchor EV-proteomes of *C. neoformans*
453 and *C. deneoformans* are nearly identical, whereas *C. deuterogattii* is more diverse (**Fig. 5D**).

454 Mature GPI-anchored proteins can also be membrane-bound and are predicted to be
455 highly mannosylated in *Cryptococcus* and other fungi (Levitz et al. 2001, de Groot et al. 2003).
456 We thus reasoned that these mannosylated proteins might compose the EV decorations
457 observed by cryo-EM. To test this hypothesis, we incubated EVs with the Concanavalin A
458 (ConA), conjugated to Alexa Fluor 488, and further analyzed by flow cytometry. Our results
459 demonstrated that more than 98% of the vesicles were recognized by this lectin, confirming the
460 presence of mannosylated proteins on EV surface (**Fig. 6**). Strikingly, EVs obtained from the
461 acapsular *cap59Δ* mutant strain also showed a high percentage of staining (94.3%), which
462 suggested that mannoproteins could essentially be the outer vesicle decoration.

463 Two of the most abundant *C. neoformans* EV-associated proteins (Mp88) and
464 Vep1/CNAG_03223) are both GPI-anchored and represent 23.7% of the total identified
465 proteins in the EV extract. Indeed, in all three species, Mp88 (Huang et al. 2002) was the most
466 prevalent protein. In *C. deuterogatii* EVs, in which the Vep1 protein is not present, Mp88
467 represents 35.4% of the total amount of protein present in the EV extract. We constructed the
468 corresponding single mutant strains for *mp88*Δ and *vep1*Δ, and tested for ConA binding.
469 However, EVs purified from both single mutants showed similar ConA binding percentages to
470 wild type EVs (data not shown), suggesting that cryptococcal EVs might bear a highly complex
471 decoration, probably formed from a dynamic combination of mannoproteins.

472 Combining all these data, we propose a model for cryptococcal EV structure, in which,
473 EVs are decorated by mannosylated proteins and covered by GXM (**Fig. 7**).

474

475 - *EVs for immunization and protection against cryptococcal infection*

476 Proteomic analysis of the *C. neoformans* EVs identified many immunogenic proteins,
477 including Mp88, the members of Gox and Cda families and some Vep proteins previously tested
478 as vaccine candidates against cryptococcosis (Specht et al. 2017, Hester et al. 2020). Moreover,
479 some of these proteins were also found to be enriched in *C. deneoformans* and *C. deuterogattii*
480 EVs (Mp88, Cda1, Cda2, Cda3, and Gox2), suggesting that secretion of these immunogenic
481 molecules via EVs could be a conserved feature across different species.

482 Taking into account that cryptococcal EVs have been shown to be immune modulators
483 (Freitas et al. 2019) and may impact the pathophysiology of the infection (Bielska et al. 2018,
484 Hai et al. 2020), we reasoned that EVs could be used as vaccines against cryptococcosis
485 avoiding the need for recombinant protein purification and adjuvant usage. The usage of fungal
486 EVs has been previously suggested as a promising vaccine strategy (Vargas et al. 2015,
487 Colombo et al. 2019, Freitas et al. 2019, Vargas et al. 2020). However, cryptococcal EVs have
488 never been tested in murine infection mode so far.

489 As a pilot experiment, we first purified EVs from *C. neoformans* WT strain and from
490 the acapsular *cap59*Δ strain, and used them to immunize BALB/c mice in two different EV-
491 protein extracts dosages (1 and 10 μg) via intraperitoneal injections; each group, including the
492 control group, contained four mice. After three immunizations, the anti-EV-antibody response
493 in the mice was evaluated. Regardless of EV origin, all the immunized mice produced
494 antibodies against vesicular molecules, as revealed by Western Blot assay (**Fig. 8A**). Forty days
495 after the last immunization, mice were challenged intranasally with 10⁴ *C. neoformans* strain
496 KN99α cells, and their survival were monitored post-infection. All EV-immunized mice

497 survived longer than the non-immunized ones and, immunization with both doses of *cap59Δ*
498 EVs prolonged mice survival in a statistically significant way (**Fig. 8B**) To note, the total
499 carbohydrate per 100 μg of EV-proteins were approximately 22 μg and 3 μg, respectively, for
500 the WT and *cap59Δ* mutant, as analyzed by gas-chromatography analyses (Richie et al. 2009).

501 We then confirmed this result using a larger number of mice (10 mice per group). Since
502 the highest dose of EVs from the acapsular mutant rendered the best protection, we decided to
503 proceed only with EVs from *cap59Δ* strain (10 μg). After repeated immunizations with EVs,
504 the mice anti-EV-antibody response was analyzed; all immunized mice produced antibodies
505 against vesicular molecules (**Fig. 8C**). Following, the mice were challenged with 10⁴ *C.*
506 *neoformans* strain KN99α cells, and their survival was monitored post-infection. The EV-based
507 immunization rendered a significant prolonged survival (p=0.0006) (**Fig. 8D**), thus confirming
508 the promising potential usage of EV-based protection against *Cryptococcus*.

509

510 **4. Discussion**

511 Studies on fungal EVs have gained much attention during the last years (Rizzo et al. 2020).
512 Although many promising data coming from pathogenic and nonpathogenic species highlight
513 their importance in diverse biological contexts, knowledge on fungal EVs is still limited, mostly
514 due to their nanometer size and the technical hurdles intrinsic to the methods applied for their
515 characterization (Rizzo et al. 2020). We here used cutting edge technologies to revisit
516 *Cryptococcus* EVs. Our cryo-EM analysis showed an unprecedented quality of EV images and
517 resolved the fibrillar structure decoration as a new aspect on fungal EVs.

518 Our hypothesis is that EV decoration is made of mannoproteins. This is supported by two
519 independent experiments. First, we demonstrated that although GXM most probably surrounds
520 the vesicles, it is not necessary for the presence of decoration. Thus, EVs produced by an
521 acapsular strains are not bound by a GXM specific antibody yet, they displayed the type of
522 decoration and, in a similar percentage of EVs. Secondly, *C. albicans* and *S. cerevisiae* EVs are
523 also decorated, although none of these strains produced a polysaccharide capsule. Nonetheless,
524 our results revealed that the deletion of single mannoproteins, such as the GPI-anchored
525 proteins Mp88 and Vep1, was not sufficient to completely remove the EV decoration,
526 suggesting that this structure has a highly complex and dynamic composition, including several
527 mannoproteins. Indeed, previous reports in *C. albicans* showed that the role of GPI-anchored
528 proteins are redundant and single mutants mostly displayed minor phenotypes, if any (Plaine et
529 al. 2008).

530 Interestingly, in 2018 Johansson and colleagues performed cryo-EM analysis of *Malassezia*
531 *sympodialis* EVs demonstrating no decoration on their surface (Johansson et al. 2018).
532 Comparative genomic analysis suggested that this lipophilic pathogenic yeast, living on the skin
533 (Theelen et al. 2018), lacks the N-glycosylation pathway and possesses only a very small
534 number of GPI-anchor proteins (Gioti et al. 2013). Accordingly, *M. sympodialis* cells lack the
535 extensive mannan outer fibrillar layer, which can be easily observed at the surface of the cell
536 wall of most yeasts including *S. cerevisiae* or *C. albicans* (Gioti et al. 2013, Muszewska et al.
537 2017). Therefore, it is very tempting to hypothesize that this absence of mannans in *M.*
538 *sympodialis* could explain the absence of EV decoration, supporting the idea that these are
539 mannoprotein-based.

540 Previous proteomic analysis of fungal EVs identified putative mannoproteins, suggesting
541 that this decoration is a common feature of fungal EVs (Bleackley et al. 2019, Dawson et al.
542 2020, Karkowska-Kuleta et al. 2020, Rizzo et al. 2020). Accordingly, it was recently shown
543 that *C. glabrata* EVs bound by the ConA lectin in flow cytometry experiments (Karkowska-
544 Kuleta et al. 2020) and that *Aspergillus fumigatus* protoplasts, when submitted to cell wall
545 regeneration, also release EVs which seem to be covered by fibril-like structures (Rizzo et al.
546 2020).

547 Whereas the presence of decoration seems to be a hallmark of fungal EV, they are not
548 specific to this kingdom. Although EVs bearing visible structures on their surface have not been
549 commonly reported, a recent cryo-EM analysis of EVs derived from human breast cell lines
550 overexpressing hyaluronan synthase 3-(HAS3) recently suggested the presence of fibril-like
551 structures on the vesicle surface (Noble et al. 2020). Additionally, EVs from poliovirus-infected
552 cells contain ‘protein structures with globular heads on a stalk’ around the membrane (Yang et
553 al. 2020). Nevertheless, it is still unclear how often this feature is present among the whole EV
554 population, and what the composition of these surface structures is.

555 Previous reports explored the size and morphology of fungal EV populations, mostly by
556 techniques comprising electron microscopy (TEM, SEM), dynamic light scattering (DLS), and
557 NTA (Albuquerque et al. 2008, Rodrigues et al. 2008, Wolf et al. 2014, Vargas et al. 2015,
558 Wolf et al. 2015, Bielska and May 2019). Here we show that cryptococcal EVs are much more
559 heterogeneous than showed before, comprising not only the regular EVs but also tubular, flat,
560 and multilayered EVs. This description is reasonably different from the conventional view that
561 EVs are only based on double-membrane spherical structures. Although the different EV
562 morphologies were previously identified in many fungal pathogens (Albuquerque et al. 2008,
563 Rodrigues et al. 2008, Tefsen et al. 2014, Vargas et al. 2015), some vesicular shapes found in

564 this work were not commonly observed in previous EVs analysis, such as tubular and flat
565 structures, and their relative proportions no evaluated.

566 Membrane tubule structures (memtubs) budding from the plasma membrane were found in
567 the arbuscular fungus *Rhizophagus irregularis*, suggesting that different shapes of membranous
568 structures could appear during fungal growth (Roth et al. 2019). Additionally, tubular and other
569 morphologies were also found in EV populations obtained from human biological fluids
570 (Arraud et al. 2014, Emelyanov et al. 2020). Although these data suggest that diverse structures
571 could be part of the native EV population, the cellular origins of these structures are still
572 unknown, and we cannot rule out the possibility of being artifacts resulted from the filtration
573 step of the commonly used EV isolation protocols.

574 In this study, we demonstrated that *C. neoformans* releases both decorated and
575 undecorated EVs adding another previously unappreciated aspect on fungal EV diversity. As
576 hypothesized before, this result also suggests the existence of two different pathways involved
577 in EV biogenesis (Oliveira et al. 2010, Oliveira et al. 2013, Bielska and May 2019, Rizzo et al.
578 2020). It is, therefore, reasonable to hypothesize that decorated EVs could have shed out from
579 the fungal plasma membrane, “stealing” cell membrane proteins when they bud out.
580 Interestingly, the decorated EVs are usually larger than the undecorated ones, which is in good
581 adequacy with what would be typical microvesicles in mammals. In this hypothesis, the
582 enrichment of tetraspanin membrane proteins containing a SUR7/Pall family motif might
583 indicate that decorated EVs could be specifically shed from the Sur7 specialized plasma
584 membrane domains. This model could be extended to other fungi as Sur7 proteins have been
585 recently identified as EV- protein markers in *C. albicans* and in the wheat pathogen
586 *Zymoseptoria tritici* (Dawson et al. 2020, Hill and Solomon 2020). This latter hypothesis,
587 together with whether or not the smaller undecorated EVs are a result of the endosomal
588 secretory pathways, considered as exosomes being released by multivesicular bodies (MVB),
589 still needs to be further explored. Interestingly, the characterization of decorated and
590 undecorated EVs as microvesicles and exosomes, respectively, were previously assumed
591 (Noble et al. 2020). This hypothesis and our current results are supported by a recent study of
592 *A. fumigatus* EVs in the absence of a cell wall. EVs were clearly formed at the plasma
593 membrane level and they contained a number of plasma membrane proteins (Rizzo et al. 2020).

594 Our work suggests that fungal EV cargo contains proteins involved in diverse biological
595 processes, including Mp88 and members of Cda and Gox families, which have been suggested
596 as immunomodulators (Specht et al. 2017, Hester et al. 2020). Since the novel surface structure
597 on fungal EV resolved by cryo-EM resembles the spike complexes on viral envelopes (Neuman

598 et al. 2006, Zanetti et al. 2006), we reasoned their use as a vaccine platform approach. Numerous
599 efforts have been carried out in developing vaccines against fungal infections. Some of these
600 challenges engaged in different stages of clinical trials; however, none of them could be finally
601 approved for public use (Nami et al. 2019). It was previously shown that the pre-treatment of
602 *Galleria mellonella* larvae with fungal EVs stimulated a protective response against a lethal
603 challenge with *C. albicans* or *C. neoformans* (Vargas et al. 2015, Colombo et al. 2019). More
604 recently, it was also demonstrated that *C. albicans* EVs were also able to elicit a protective
605 effect against murine candidiasis (Vargas et al. 2020). Interestingly, *C. neoformans* EV have
606 shown to be immune reactive with sera from patients with cryptococcosis, indicating that EV-
607 associated proteins are produced during cryptococcal infection and that they might be used as
608 vaccines (Rodrigues et al. 2008). Prophylactic immunization is one of the effective methods to
609 prevent cryptococcal infection, and several cryptococcal antigens have been tested for their
610 vaccination potential (Caballero Van Dyke and Wormley 2018, Ueno et al. 2020). However,
611 the *in vivo* immunoregulatory role of EVs have largely remained unknown (Robbins and
612 Morelli 2014).

613 In our study, antibody responses in cryptococcal EV-immunized mice indicate that the
614 EVs are capable of eliciting an adaptive immune response in the absence of any adjuvants or
615 carriers, unlike other antigenic proteins of *Cryptococcus* (Specht et al. 2017). EV-based
616 vaccination data obtained by other groups using an invertebrate model suggest that innate
617 immunity might also be involved (Vargas et al. 2015, Colombo et al. 2019). As *Cryptococcus*
618 predominantly infects immunocompromised hosts, it will be worth checking the role of EVs in
619 eliciting trained immunity, wherein innate immune cells develop memory-like response against
620 an antigen upon repeated exposure (Hole et al. 2019, Mulder et al. 2019). The mechanisms, and
621 the responsible immune cell types leading to prolonged survival in our murine infection model
622 remain thus to be identified. Although EVs immunizations were not sufficient to prevent the
623 animal death, we believe that adjusting the antigens exposed on EV surface could potentially
624 increase the protective effect. In that sense, the fact EV from *C. neoformans* WT strain showed
625 a reduced effect on mice survival, compared to EVs obtained from the acapsular mutant, which
626 is a very encouraging data.

627 Overall, the fantastic power of cryo-EM, together with a number of innovative analyses,
628 allowed us to draw a new model of fungal EVs and revealed new aspects of their diversity,
629 suggesting different biosynthetic pathways. This model supports new strategies to construct
630 vaccines against these still too often neglected infectious diseases. It also opens the door to
631 more questions concerning the origin and the fate of the fungal EVs.

632 5. References

633

634

- 635 Albuquerque PC, Nakayasu ES, Rodrigues ML, Frases S, Casadevall A, Zancoppe-Oliveira RM, Almeida IC,
636 Nosanchuk JD 2008. Vesicular transport in *Histoplasma capsulatum*: an effective mechanism for trans-
637 cell wall transfer of proteins and lipids in ascomycetes. *Cell Microbiol* 10: 1695-1710.
- 638 Almagro Armenteros JJ, Tsirigos KD, Sønderby CK, Petersen TN, Winther O, Brunak S, von Heijne G,
639 Nielsen H 2019. SignalP 5.0 improves signal peptide predictions using deep neural networks. *Nature*
640 *Biotechnology* 37: 420-423.
- 641 Arraud N, Linares R, Tan S, Gounou C, Pasquet JM, Mornet S, Brisson AR 2014. Extracellular vesicles
642 from blood plasma: determination of their morphology, size, phenotype and concentration. *Journal of*
643 *Thrombosis and Haemostasis* 12: 614-627.
- 644 Bachurski D, Schuldner M, Nguyen P-H, Malz A, Reiners KS, Grenzi PC, Babatz F, Schauss AC, Hansen
645 HP, et al. 2019. Extracellular vesicle measurements with nanoparticle tracking analysis - An accuracy
646 and repeatability comparison between NanoSight NS300 and ZetaView. *Journal of extracellular vesicles*
647 8: 1596016-1596016.
- 648 Baker LG, Specht CA, Lodge JK 2011. Cell Wall Chitosan Is Necessary for Virulence in the Opportunistic
649 Pathogen *Cryptococcus neoformans*. *Eukaryot Cell* 10: 1264.
- 650 Bielska E, May RC 2019. Extracellular vesicles of human pathogenic fungi. *Curr Opin Microbiol* 52:
651 90-99.
- 652 Bielska E, Sisquella MA, Aldeieg M, Birch C, O'Donoghue EJ, May RC 2018. Pathogen-derived
653 extracellular vesicles mediate virulence in the fatal human pathogen *Cryptococcus gattii*. *Nature*
654 *communications* 9: 1556-1556.
- 655 Bleackley MR, Dawson CS, Anderson MA 2019. Fungal Extracellular Vesicles with a Focus on Proteomic
656 Analysis. *PROTEOMICS* 19: 1800232.
- 657 Bleackley MR, Samuel M, Garcia-Ceron D, McKenna JA, Lowe RGT, Pathan M, Zhao K, Ang C-S,
658 Mathivanan S, et al. 2020. Extracellular Vesicles From the Cotton Pathogen *Fusarium oxysporum* f. sp.
659 *vasinfectum* Induce a Phytotoxic Response in Plants. *Frontiers in plant science* 10: 1610-1610.
- 660 Caballero Van Dyke MC, Wormley FL, Jr. 2018. A Call to Arms: Quest for a Cryptococcal Vaccine. *Trends*
661 *Microbiol* 26: 436-446.
- 662 Casadevall A, Mukherjee J, Devi SJN, Schneerson R, Robbins JB, Scharff MD 1992. Antibodies Elicited
663 by a *Cryptococcus neoformans*-Tetanus Toxoid Conjugate Vaccine Have the Same Specificity as Those
664 Elicited in Infection. *The Journal of Infectious Diseases* 165: 1086-1093.
- 665 Chiang C-Y, Chen C 2019. Toward characterizing extracellular vesicles at a single-particle level. *J Biomed*
666 *Sci* 26: 9-9.
- 667 Chiou N-T, Kageyama R, Ansel KM 2018. Selective Export into Extracellular Vesicles and Function of
668 tRNA Fragments during T Cell Activation. *Cell Rep.* 25: 3356-3370.e3354.
- 669 Chun CD, Brown JCS, Madhani HD 2011. A major role for capsule-independent phagocytosis-inhibitory
670 mechanisms in mammalian infection by *Cryptococcus neoformans*. *Cell host & microbe* 9: 243-251.
- 671 Coakley G, McCaskill JL, Borger JG, Simbari F, Robertson E, Millar M, Harcus Y, McSorley HJ, Maizels
672 RM, et al. 2017. Extracellular Vesicles from a Helminth Parasite Suppress Macrophage Activation and
673 Constitute an Effective Vaccine for Protective Immunity. *Cell Rep.* 19: 1545-1557.
- 674 Collopy PD, Colot HV, Park G, Ringelberg C, Crew CM, Borkovich KA, Dunlap JC 2010. High-throughput
675 construction of gene deletion cassettes for generation of *Neurospora crassa* knockout strains. *Methods*
676 *Mol Biol* 638: 33-40.
- 677 Colombo AC, Rella A, Normile T, Joffe LS, Tavares PM, de S. Araújo GR, Frases S, Orner EP, Farnoud AM,
678 et al. 2019. *Cryptococcus neoformans* Glucuronoxylomannan and Sterylglucoside Are Required for
679 Host Protection in an Animal Vaccination Model. *mBio* 10: e02909-02918.
- 680 Cox J, Mann M 2008. MaxQuant enables high peptide identification rates, individualized p.p.b.-range
681 mass accuracies and proteome-wide protein quantification. *Nature Biotechnology* 26: 1367-1372.

682 Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV, Mann M 2011. Andromeda: A Peptide Search
683 Engine Integrated into the MaxQuant Environment. *Journal of Proteome Research* 10: 1794-1805.
684 da Silva RP, Puccia R, Rodrigues ML, Oliveira DL, Joffe LS, César GV, Nimrichter L, Goldenberg S, Alves
685 LR 2015. Extracellular vesicle-mediated export of fungal RNA. *Sci. Rep.* 5: 7763.
686 Dawson CS, Garcia-Ceron D, Rajapaksha H, Faou P, Bleackley MR, Anderson MA 2020. Protein markers
687 for *Candida albicans* EVs include claudin-like Sur7 family proteins. *Journal of Extracellular Vesicles* 9:
688 1750810.
689 de Groot PWJ, Hellingwerf KJ, Klis FM 2003. Genome-wide identification of fungal GPI proteins. *Yeast*
690 20: 781-796.
691 Deatherage BL, Cookson BT 2012. Membrane Vesicle Release in Bacteria, Eukaryotes, and Archaea: a
692 Conserved yet Underappreciated Aspect of Microbial Life. *Infect Immun* 80: 1948.
693 Eisenman HC, Frases S, Nicola AM, Rodrigues ML, Casadevall A 2009. Vesicle-associated melanization
694 in *Cryptococcus neoformans*. *Microbiology* 155: 3860-3867.
695 Emelyanov A, Shtam T, Kamyshinsky R, Garaeva L, Verlov N, Miliukhina I, Kudrevatykh A, Gavrilov G,
696 Zabrodskaya Y, et al. 2020. Cryo-electron microscopy of extracellular vesicles from cerebrospinal fluid.
697 *PLOS ONE* 15: e0227949.
698 Fan Y, Lin X 2018. Multiple Applications of a Transient CRISPR-Cas9 Coupled with Electroporation
699 (TRACE) System in the *Cryptococcus neoformans* Species Complex. *Genetics* 208: 1357.
700 Ferrareze PAG, Maufrais C, Silva Araujo Streit R, Priest S, Cuomo C, Heitman J, Staats CC, Janbon G
701 2020. A validate pipeline for annotation of complex fungal genomes: application to *Cryptococcus*
702 *deuterogatii* genome annotation *submitted*.
703 Freitas MS, Bonato VLD, Pessoni AM, Rodrigues ML, Casadevall A, Almeida F 2019. Fungal Extracellular
704 Vesicles as Potential Targets for Immune Interventions. *mSphere* 4: e00747-00719.
705 Gioti A, Nystedt B, Li W, Xu J, Andersson A, Averette AF, Münch K, Wang X, Kappauf C, et al. 2013.
706 Genomic Insights into the Atopic Eczema-Associated Skin Commensal Yeast & Malassezia
707 *sympodialis*. *mBio* 4: e00572-00512.
708 Hai TP, Tuan TL, Van Anh D, Mai TN, Phu Huong LN, Thwaites GE, Johnson E, Van Vinh Chau N, Ashton
709 P, et al. 2020. The expression of virulence by the *Cryptococcus neoformans* VN1a-5 lineage is plastic
710 and associated with host immune background. *bioRxiv*: 2020.2002.2024.962134.
711 Hester MM, Lee CK, Abraham A, Khoshkenar P, Ostroff GR, Levitz SM, Specht CA 2020. Protection of
712 mice against experimental cryptococcosis using glucan particle-based vaccines containing novel
713 recombinant antigens. *Vaccine* 38: 620-626.
714 Hill E, Solomon P (2020). Extracellular Vesicles from the Apoplactic Fungal Wheat Pathogen
715 *Zyoseptoria Tritici*, Research Square.
716 Hole CR, Wager CML, Castro-Lopez N, Campuzano A, Cai H, Wozniak KL, Wang Y, Wormley FL 2019.
717 Induction of memory-like dendritic cell responses in vivo. *Nature Communications* 10: 2955.
718 Huang C, Nong SH, Mansour MK, Specht CA, Levitz SM 2002. Purification and characterization of a
719 second immunoreactive mannoprotein from *Cryptococcus neoformans* that stimulates T-cell
720 responses. *Infect Immun* 70: 5485-5493.
721 Joffe LS, Nimrichter L, Rodrigues ML, Del Poeta M 2016. Potential Roles of Fungal Extracellular Vesicles
722 during Infection. *mSphere* 1: e00099-00016.
723 Johansson HJ, Vallhov H, Holm T, Gehrman U, Andersson A, Johansson C, Blom H, Carroni M, Lehtiö
724 J, et al. 2018. Extracellular nanovesicles released from the commensal yeast *Malassezia sympodialis*
725 are enriched in allergens and interact with cells in human skin. *Sci. Rep.* 8: 9182.
726 Jung WH, Sham A, Lian T, Singh A, Kosman DJ, Kronstad JW 2008. Iron Source Preference and
727 Regulation of Iron Uptake in *Cryptococcus neoformans*. *PLoS Pathog* 4: e45.
728 Karkowska-Kuleta J, Kulig K, Karnas E, Zuba-Surma E, Woznicka O, Pyza E, Kuleta P, Osyczka A, Rapala-
729 Kozik M, et al. 2020. Characteristics of extracellular vesicles released by the pathogenic yeast-like fungi
730 *Candida glabrata*, *Candida parapsilosis* and *Candida tropicalis*. *Cells* 9: 1722.
731 Kremer JR, Mastronarde DN, McIntosh JR 1996. Computer Visualization of Three-Dimensional Image
732 Data Using IMOD. *Journal of Structural Biology* 116: 71-76.

733 Krogh A, Larsson B, von Heijne G, Sonnhammer ELL 2001. Predicting transmembrane protein topology
734 with a hidden markov model: application to complete genomes. *J Mol Biol* 305: 567-580.
735 Leone F, Bellani L, Muccifora S, Giorgetti L, Bongioanni P, Simili M, Maserti B, Del Carratore R 2018.
736 Analysis of extracellular vesicles produced in the biofilm by the dimorphic yeast *Pichia fermentans*.
737 *Journal of Cellular Physiology* 233: 2759-2767.
738 Levitz SM, Nong S, Mansour MK, Huang C, Specht CA 2001. Molecular characterization of a
739 mannoprotein with homology to chitin deacetylases that stimulates T cell responses to *Cryptococcus*
740 *neoformans*. *Proc Natl Acad Sci USA* 98: 10422-10427.
741 Maas SLN, de Vrij J, van der Vlist EJ, Geragousian B, van Bloois L, Mastrobattista E, Schiffelers RM,
742 Wauben MHM, Broekman MLD, et al. 2015. Possibilities and limitations of current technologies for
743 quantification of biological extracellular vesicles and synthetic mimics. *Journal of Controlled Release*
744 200: 87-96.
745 Mastronarde DN 2005. Automated electron microscope tomography using robust prediction of
746 specimen movements. *Journal of Structural Biology* 152: 36-51.
747 Mastronarde DN, Held SR 2017. Automated tilt series alignment and tomographic reconstruction in
748 IMOD. *Journal of structural biology* 197: 102-113.
749 Meldolesi J 2018. Exosomes and Ectosomes in Intercellular Communication. *Curr Biol* 28: R435-R444.
750 Moyrand F, Fontaine T, Janbon G 2007. Systematic capsule gene disruption reveals the central role of
751 galactose metabolism on *Cryptococcus neoformans* virulence. *Mol Microbiol* 64: 771-781.
752 Mulder WJM, Ochando J, Joosten LAB, Fayad ZA, Netea MG 2019. Therapeutic targeting of trained
753 immunity. *Nat Rev Drug Discov* 18: 553-566.
754 Muszewska A, Piłsyk S, Perlińska-Lenart U, Kruszewska JS 2017. Diversity of Cell Wall Related Proteins
755 in Human Pathogenic Fungi. *Journal of fungi (Basel, Switzerland)* 4: 6.
756 Nami S, Mohammadi R, Vakili M, Khezripour K, Mirzaei H, Morovati H 2019. Fungal vaccines,
757 mechanism of actions and immunology: A comprehensive review. *Biomedicine & Pharmacotherapy*
758 109: 333-344.
759 Neuman BW, Adair BD, Yoshioka C, Quispe JD, Orca G, Kuhn P, Milligan RA, Yeager M, Buchmeier MJ
760 2006. Supramolecular architecture of severe acute respiratory syndrome coronavirus revealed by
761 electron cryomicroscopy. *J Virol* 80: 7918-7928.
762 Noble JM, Roberts LM, Vidavsky N, Chiou AE, Fischbach C, Paszek MJ, Estroff LA, Kourkoutis LF 2020.
763 Direct comparison of optical and electron microscopy methods for structural characterization of
764 extracellular vesicles. *Journal of Structural Biology* 210: 107474.
765 O'Meara TR, Alspaugh JA 2012. The *Cryptococcus neoformans* capsule: a sword and a shield. *Clin*
766 *Microbiol Rev* 25: 387-408.
767 Oliveira DL, Freire-de-Lima CG, Nosanchuk JD, Casadevall A, Rodrigues ML, Nimrichter L 2010.
768 Extracellular vesicles from *Cryptococcus neoformans* modulate macrophage functions. *Infect Immun*
769 78: 1601-1609.
770 Oliveira DL, Nakayasu ES, Joffe LS, Guimarães AJ, Sobreira TJP, Nosanchuk JD, Cordero RJB, Frases S,
771 Casadevall A, et al. 2010. Characterization of Yeast Extracellular Vesicles: Evidence for the Participation
772 of Different Pathways of Cellular Traffic in Vesicle Biogenesis. *PLOS ONE* 5: e11113.
773 Oliveira DL, Nimrichter L, Miranda K, Frases S, Faull KF, Casadevall A, Rodrigues ML 2009. *Cryptococcus*
774 *neoformans* cryoultramicrotomy and vesicle fractionation reveals an intimate association between
775 membrane lipids and glucuronoxylomannan. *Fungal Genet Biol* 46: 956-963.
776 Oliveira DL, Rizzo J, Joffe LS, Godinho RMC, Rodrigues ML 2013. Where do they come from and where
777 do they go: candidates for regulating extracellular vesicle formation in fungi. *Int J Mol Sci* 14: 9581-
778 9603.
779 Orlov I, Myasnikov AG, Andronov L, Natchiar SK, Khatter H, Beinsteiner B, Ménétret J-F, Hazemann I,
780 Mohideen K, et al. 2017. The integrative role of cryo electron microscopy in molecular and cellular
781 structural biology. *Biology of the Cell* 109: 81-93.
782 Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE 2004. UCSF
783 Chimera—A visualization system for exploratory research and analysis. *Journal of Computational*
784 *Chemistry* 25: 1605-1612.

785 Pierleoni A, Martelli PL, Casadio R 2008. PredGPI: a GPI-anchor predictor. *BMC Bioinformatics* 9: 392.
786 Plaine A, Walker L, Da Costa G, Mora-Montes HM, McKinnon A, Gow NAR, Gaillardin C, Munro CA,
787 Richard ML 2008. Functional analysis of *Candida albicans* GPI-anchored proteins: roles in cell wall
788 integrity and caspofungin sensitivity. *Fungal genetics and biology : FG & B* 45: 1404-1414.
789 Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, Denning DW, Loyse A, Boulware
790 DR 2017. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. *The*
791 *Lancet Infectious Diseases* 17: 873-881.
792 Rayner S, Bruhn S, Vallhov H, Andersson A, Billmyre RB, Scheynius A 2017. Identification of small RNAs
793 in extracellular vesicles from the commensal yeast *Malassezia sympodialis*. *Sci. Rep.* 7: 39742.
794 Reis FCG, Borges BS, Jozefowicz LJ, Sena BAG, Garcia AWA, Medeiros LC, Martins ST, Honorato L,
795 Schrank A, et al. 2019. A Novel Protocol for the Isolation of Fungal Extracellular Vesicles Reveals the
796 Participation of a Putative Scramblase in Polysaccharide Export and Capsule Construction in
797 *Cryptococcus gattii*. *mSphere* 4: e00080-00019.
798 Richie DL, Hartl L, Amanianda V, Winters MS, Fuller KK, Miley MD, White S, McCarthy JW, Latgé J-P, et
799 al. 2009. A role for the unfolded protein response (UPR) in virulence and antifungal susceptibility in
800 *Aspergillus fumigatus*. *PLoS Pathog* 5: e1000258-e1000258.
801 Rizzo J, Albuquerque PC, Wolf JM, Nascimento R, Pereira MD, Nosanchuk JD, Rodrigues ML 2017.
802 Analysis of multiple components involved in the interaction between *Cryptococcus neoformans* and
803 *Acanthamoeba castellanii*. *Fungal Biology* 121: 602-614.
804 Rizzo J, Chaze T, Miranda K, Roberson RW, Gorgette O, Nimrichter L, Matondo M, Latgé J-P, Beauvais
805 A, et al. 2020. Characterization of extracellular vesicles produced by *Aspergillus fumigatus* protoplasts.
806 *mSphere* 5: e00476-00420.
807 Rizzo J, Rodrigues ML, Janbon G 2020. Extracellular Vesicles in Fungi: Past, Present, and Future
808 Perspectives. *Frontiers in Cellular and Infection Microbiology* 10.
809 Robbins PD, Morelli AE 2014. Regulation of immune responses by extracellular vesicles. *Nat Rev*
810 *Immunol* 14: 195-208.
811 Rodrigues ML, Casadevall A 2018. A two-way road: novel roles for fungal extracellular vesicles. *Mol*
812 *Microbiol* 110: 11-15.
813 Rodrigues ML, Godinho RMC, Zamith-Miranda D, Nimrichter L 2015. Traveling into Outer Space:
814 Unanswered Questions about Fungal Extracellular Vesicles. *PLoS Pathog* 11: e1005240.
815 Rodrigues ML, Nakayasu ES, Oliveira DL, Nimrichter L, Nosanchuk JD, Almeida IC, A. C 2008.
816 Extracellular vesicles produced by *Cryptococcus neoformans* contain protein components associated
817 with virulence. *Eukaryot Cell* 7: 58-67.
818 Rodrigues ML, Nimrichter L, Oliveira DL, Frases S, Miranda K, Zaragoza O, Alvarez M, Nakouzi A,
819 Feldmesser M, et al. 2007. Vesicular polysaccharide export in *Cryptococcus neoformans* is a eukaryotic
820 solution to the problem of fungal trans-cell wall transport. *Eukaryot Cell* 6: 48-59.
821 Roth R, Hillmer S, Funaya C, Chiapello M, Schumacher K, Lo Presti L, Kahmann R, Paszkowski U 2019.
822 Arbuscular cell invasion coincides with extracellular vesicles and membrane tubules. *Nature Plants* 5:
823 204-211.
824 Schorb M, Haberbosch I, Hagen WJH, Schwab Y, Mastronarde DN 2019. Software tools for automated
825 transmission electron microscopy. *Nature Meth* 16: 471-477.
826 Schwanhäusser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, Selbach M 2011. Global
827 quantification of mammalian gene expression control. *Nature* 473: 337-342.
828 Shopova IA, Belyaev I, Dasari P, Jahreis S, Stroe MC, Cseresnyés Z, Zimmermann A-K, Medyukhina A,
829 Svensson C-M, et al. 2020. Human Neutrophils Produce Antifungal Extracellular Vesicles against
830 *Aspergillus fumigatus*. *mBio* 11: e00596-00520.
831 Souza JAM, Baltazar LdM, Carregal VM, Gouveia-Eufrasio L, de Oliveira AG, Dias WG, Campos Rocha
832 M, Rocha de Miranda K, Malavazi I, et al. 2019. Characterization of *Aspergillus fumigatus* extracellular
833 vesicles and their effects on macrophages and neutrophils functions. *Frontiers in microbiology* 10:
834 2008-2008.
835 Specht CA, Lee CK, Huang H, Hester MM, Liu J, Luckie BA, Torres Santana MA, Mirza Z, Khoshkenar P,
836 et al. 2017. Vaccination with Recombinant *Cryptococcus* Proteins in Glucan Particles Protects Mice

- 837 against Cryptococcosis in a Manner Dependent upon Mouse Strain and Cryptococcal Species. *mBio* 8:
838 e01872-01817.
- 839 Tefsen B, Grijpstra J, Ordonez S, Lammers M, van Die I, de Cock H 2014. Deletion of the CAP10 gene of
840 *Cryptococcus neoformans* results in a pleiotropic phenotype with changes in expression of virulence
841 factors. *Research in Microbiology* 165: 399-410.
- 842 Theelen B, Cafarchia C, Gaitanis G, Bassukas ID, Boekhout T, Dawson TL, Jr. 2018. *Malassezia* ecology,
843 pathophysiology, and treatment. *Med Mycol* 56: S10-S25.
- 844 Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arab T,
845 Archer F, et al. 2018. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a
846 position statement of the International Society for Extracellular Vesicles and update of the MISEV2014
847 guidelines. *Journal of extracellular vesicles* 7: 1535750-1535750.
- 848 Tyanova S, Temu T, Cox J 2016. The MaxQuant computational platform for mass spectrometry-based
849 shotgun proteomics. *Nature Protocols* 11: 2301-2319.
- 850 Ueno K, Yanagihara N, Shimizu K, Miyazaki Y 2020. Vaccines and protective immune memory against
851 Cryptococcosis. *Biol. Pharm. Bull.* 43.
- 852 Vallejo MC, Nakayasu ES, Longo LVG, Ganiko L, Lopes FG, Matsuo AL, Almeida IC, Puccia R 2012.
853 Lipidomic analysis of extracellular vesicles from the pathogenic phase of *Paracoccidioides brasiliensis*.
854 *PLoS one* 7: e39463-e39463.
- 855 Van Der Pol E, Hoekstra AG, Sturk A, Otto C, Van Leeuwen TG, Nieuwland R 2010. Optical and non-
856 optical methods for detection and characterization of microparticles and exosomes. *Journal of*
857 *Thrombosis and Haemostasis* 8: 2596-2607.
- 858 van Niel G, D'Angelo G, Raposo G 2018. Shedding light on the cell biology of extracellular vesicles.
859 *Nature Reviews Molecular Cell Biology* 19: 213-228.
- 860 Vargas G, Honorato L, Guimarães AJ, Rodrigues ML, Reis FCG, Vale AM, Ray A, Nosanchuk JD,
861 Nimrichter L 2020. Protective effect of fungal extracellular vesicles against murine candidiasis. *Cell*
862 *Microbiol n/a*: e13238.
- 863 Vargas G, Rocha JDB, Oliveira DL, Albuquerque PC, Frases S, Santos SS, Nosanchuk JD, Gomes AMO,
864 Medeiros LCAS, et al. 2015. Compositional and immunobiological analyses of extracellular vesicles
865 released by *Candida albicans*. *Cell Microbiol* 17: 389-407.
- 866 Wallace EWJ, Maufrais C, Sales-Lee J, Tuck LR, de Oliveira L, Feuerbach F, Moyrand F, Natarajan P,
867 Madhani HD, et al. 2020. Quantitative global studies reveal differential translational control by start
868 codon context across the fungal kingdom. *Nucleic Acids Res.* 48: 2312-2331.
- 869 Wang X, Thompson CD, Weidenmaier C, Lee JC 2018. Release of *Staphylococcus aureus* extracellular
870 vesicles and their application as a vaccine platform. *Nature communications* 9: 1379-1379.
- 871 Witwer KW, Théry C 2019. Extracellular vesicles or exosomes? On primacy, precision, and popularity
872 influencing a choice of nomenclature. *Journal of Extracellular Vesicles* 8: 1648167.
- 873 Wolf JM, Espadas-Moreno J, Luque-Garcia JL, Casadevall A 2014. Interaction of *Cryptococcus*
874 *neoformans* extracellular vesicles with the cell wall. *Eukaryot Cell* 13: 1484-1493.
- 875 Wolf JM, Espadas J, Luque-Garcia J, Reynolds T, Casadevall A 2015. Lipid biosynthetic genes affect
876 *Candida albicans* extracellular vesicle morphology, cargo, and immunostimulatory properties.
877 *Eukaryot Cell* 14: 745-754.
- 878 Xu R, Rai A, Chen M, Suwakulsiri W, Greening DW, Simpson RJ 2018. Extracellular vesicles in cancer —
879 implications for future improvements in cancer care. *Nature Reviews Clinical Oncology* 15: 617-638.
- 880 Yang JE, Rossignol ED, Chang D, Zaia J, Forrester I, Raja K, Winbigler H, Nicastro D, Jackson WT, et al.
881 2020. Complexity and ultrastructure of infectious extracellular vesicles from cells infected by non-
882 enveloped virus. *Sci. Rep.* 10: 7939.
- 883 Zabeo D, Cvjetkovic A, Lässer C, Schorb M, Lötval J, Höög JL 2017. Exosomes purified from a single cell
884 type have diverse morphology. *Journal of extracellular vesicles* 6: 1329476-1329476.
- 885 Zanetti G, Briggs JAG, Grünwald K, Sattentau QJ, Fuller SD 2006. Cryo-Electron Tomographic Structure
886 of an Immunodeficiency Virus Envelope Complex In Situ. *PLoS Pathog* 2: e83.

887 Zarnowski R, Sanchez H, Covelli AS, Dominguez E, Jaromin A, Bernhardt J, Mitchell KF, Heiss C, Azadi P,
888 et al. 2018. *Candida albicans* biofilm–induced vesicles confer drug resistance through matrix
889 biogenesis. *PLoS Biol* 16: e2006872.

890 Zhao K, Bleackley M, Chisanga D, Gangoda L, Fonseka P, Liem M, Kalra H, Al Saffar H, Keerthikumar S,
891 et al. 2019. Extracellular vesicles secreted by *Saccharomyces cerevisiae* are involved in cell wall
892 remodelling. *Communications Biology* 2: 305.

893

894 **Geolocalisation**

895 Juliana RIZZO ORCID 0000-0001-5538-6471

896 Sarah Sze Wah WONG ORCID 0000-0002-9440-1774

897 Anastasia D. GAZI ORCID 0000-0002-2922-3625

898 Thibault CHAZE ORCID 0000-0002-3615-7021

899 Pierre-Henri COMMERE ORCID 0000-0002-3886-4256

900 Sophie NOVAULT ORCID 0000-0001-5708-3597

901 Mariette MATONDO ORCID 0000-0003-3958-7710

902 Gerard PEHAUD-ARNAUDET ORCID 0000-0001-6479-9470

903 Lysangela R ALVES ORCID 0000-0002-1972-2658

904 Robin C. MAY ORCID 0000-0001-5364-1838

905 Leonardo NIMRICHTER ORCID 0000-0001-9281-6856

906 Marcio L. RODRIGUES : ORCID 0000-0002-6081-3439

907 Vishukumar AIMANIANDA : ORCID 0000-0001-5813-7497

908 Guilhem JANBON : ORCID 0000-0002-4788-1154

909

910

911


912 **Acknowledgements**

913

914 This work was supported by a CAPES COFECUB grant n°39712ZK (to GJ, MLR, LA and
915 LN). JR was supported by the CAPES-COFECUB Franco-Brazilian Research Exchange
916 Program (88887.357947/2019-00). SSWW was supported by CEFIPRA/ANR-DFG-AfuINF
917 grant and Pasteur-Roux-Cantarini postdoctoral fellowship. VA was supported by ANR-DFG
918 AfuINF and Indo-French Centre for the Promotion of Advanced Research (CEFIPRA; Grant
919 N°5403-1) grants. Jean-Marie Winter from the NanoImaging Core at Institut Pasteur is
920 acknowledged for his support image acquisition. The NanoImaging Core was created with the
921 help of a grant from the French Government’s ‘Investissements d’Avenir’ program (EQUIPEX
922 CACSICE – “Centre d’analyse de systèmes complexes dans les environnements complexes”,
923 ANR-11-EQPX-0008). The Falcon II equipping the F20 microscope at the UBI used during

924 this study was also financed by the Equipex CACSICE (grant number ANR-11-EQPX-0008).
925 M.L.R. is supported by grants from the Brazilian Ministry of Health (grant 440015/2018-9),
926 Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; grants 405520/2018-
927 2 and 301304/2017-3), and Fiocruz (grants VPPCB-007-FIO-18 and VPPIS-001-FIO18)MLR,
928 JR, and FCGR also acknowledge support from Coordenação de Aperfeiçoamento de Pessoal
929 de Nível Superior (CAPES, finance code 001) and the Instituto Nacional de Ciência e
930 Tecnologia de Inovação em Doenças de Populações Negligenciadas (INCT-IDPN). MLR is
931 currently on leave of an associate professor position at the Instituto de Microbiologia Paulo de
932 Góes of the Universidade Federal do Rio de Janeiro
933
934

935 **6. Figures and Legends**




936

937 Figure 1: Gallery of EV categories. Cryo-EM analysis of 533 single EVs obtained from *C.*
938 *neoformans*. EVs were characterized according to their morphological aspects in regular
939 (rounded- bilayer vesicles) and irregular (not rounded – bilayer or multilayered vesicles)
940 categories. Regular vesicles represented 81.4% of all EV analyzed. The irregular vesicles were
941 subclassified as short tubular (6.9%), long tubular (2.3%), flat (4.7%), multilayer (1.7%), or
942 vesicles with miscellaneous morphologies (3.0%). Scale bars represent 100nm.

943


944



945

946 **Figure 2: Cryo-electron microscopy analysis of *C. neoformans* EVs.**


947 Cryo-EM analysis revealed a heterogeneous population of vesicles with diverse structural
948 aspects, previously unappreciated in fungal vesicles (A). As evidenced by the magnifications,
949 the EVs were delimited by a lipid bilayer (B to E), which showed either no decoration (in
950 10.8% vesicles, panels B and C) or a fibrillar decoration (pointed by arrows) in 89.2% of the
951 EVs analyzed (panels D and E). Three-dimensional organization of the fibrillar decoration
952 (yellow) on the membrane (purple) of EVs as revealed by cryo-electron tomography analysis
953 (F), magnified in the panels G and H. Full surface representation models as seen from top view
954 (G). Same models clipped with clipping plane oriented perpendicular to line of sight (H).



955

956 **Figure 3: Analysis of size and structural diversity of *C. neoformans* EVs.**


957 (A) NTA analysis of purified EVs revealed a size diameter ranging from 80 to 500 nm, with
 958 the highest distribution around 150 nm. (B) Frequency distribution of EV diameters determined
 959 by CryoEM, a total of 434 regular EVs were analyzed. The analysis based on CryoEM
 960 tomograms revealed a wider range of EV size distribution, from 10 to 500 nm diameter, with
 961 the highest relative frequency below 100 nm. (C) Cryo-EM images exemplifying EV size
 962 range. Scale bars corresponding to 100 nm. (D) EV size distribution according to the presence
 963 or absence of surface decoration. (E) Non-decorated EVs have a smaller diameter size
 964 distribution compared to decorated ones. (F) Analysis of decoration thickness from Cryo-EM
 965 images from 105 single EVs. (G) Analysis of a potential relationship between decoration
 966 thickness and EV diameter by linear regression. Error bars are represented as means \pm SD.
 967 Sample size (n) is indicated and, in brackets, the number of vesicles in that category that
 968 exceeded 500 nm in size.



969
970
971
972
973
974
975
976
977
978
979
980
981

Figure 4: Flow cytometry analysis of *C. neoformans* EVs incubated with anti-GXM monoclonal antibody.


FACS analysis of WT and the acapsular *cap59Δ* EVs in PBS or in the presence of the monoclonal antibody raised against the capsular polysaccharide 18b7 (+ mAb anti-GXM). (A) The analysis revealed strong labeling of WT vesicles (74.7%), compared to the weak labeling in the mutant (2.33%), (B). Despite the important labeling difference, *C. neoformans* WT and *cap59Δ* strains released EVs bearing similar surface decoration, shown by the cryo-EM (arrows), as well as EVs obtained from other fungal species such as *C. albicans* and *S. cerevisiae* (C). Scale bar represents 100 nm. This experiment was repeated two times with similar results.



982

983 **Figure 5: Analysis of *Cryptococcus spp* protein cargo.**

984 (A) Venn diagram revealing the EV-associated proteins overlap among *C. neoformans*, *C.*
985 *deneoformans*, and *C. deuterogattii*. Seventeen proteins were identified to be associated with
986 EVs in all three *Cryptococcus* species (B) List of the gene loci and the corresponding proteins
987 commonly found in EVs released by the three species, which could be considered as putative
988 cryptococcal EV-protein markers. Most of the proteins are predicted to be GPI anchor protein,
989 to contain a signal peptide or to possess other membrane domains, according to preGPI, signalP
990 and TMHMM website, respectively. (C) Six protein families appeared to be typical of
991 *Cryptococcus* EVs, including the Chitin deactelylase family (Cda), the Ricin-type beta-trefoil
992 lectin domain-containing protein family (Ril), the putative glyoxal oxidase family (Gox), the
993 tetraspanin membrane proteins containing a SUR7/PaII family motif (Tsh), the pr4/barwin
994 domain protein family (Blp), and the multicopper oxidase (Cfo). Among these families, the
995 proteins present in all three species are shown in green, proteins present in two species in
996 orange) and proteins present in only one species in yellow. (D) We also identify 21 putative
997 GPI-anchored proteins, as predicted by PredGPI, and 10 of them were present in all three
998 species.




999

1000 **Figure 6. Flow cytometry analysis of *C. neoformans* EVs incubated with GFP-labelled**
1001 **ConA.**

1002 FACS analysis of EVs obtained from WT and *cap59Δ* cells. EVs were incubated with ConA-
1003 Alexa Fluor 488 conjugated lectin and mixed in BD Trucount tubes (BD Biosciences),
1004 contained a known number of fluorescent beads. The number of beads for each reading was
1005 fixed to 50 (gate R4), and the percentage of ConA labeling and the number of labeled particles
1006 (count) were recorded. This experiment was repeated three times with similar results.

1007

1008




1009

1010 **Figure 7: Model of simplified molecular structure and composition of *Cryptococcus* EVs.**

1011 In accordance to previous reports and in the light of our data, a new model of *Cryptococcus*
 1012 EVs is suggested, where the outer layer is composed by the capsular polysaccharide
 1013 glucuronoxylomannan (GXM), and the lipid bilayer is covered by many proteins, including
 1014 mannoproteins, making the visual fibrillar structure resolved by cryo-EM. Most of the proteins
 1015 are predicted to be GPI-anchored, to contain a signal peptide or to possess other membrane
 1016 domains, according to preGPI, signalP and TMHMM, respectively. Three proteins the
 1017 hypothetical protein Cpc1, the putative V-type ATPase (Vma10) and the Vep3 are predicted to
 1018 be soluble. It is still unclear if these proteins are indeed inside the vesicular lumen or linked to
 1019 any other transmembrane protein. For simplification, the lipid content was not explored, but
 1020 previous works shown the presence of sterol, phospholipoids and sphingolipids. Additionally,
 1021 *Cryptococcus* EVs were also described to contain other cargoes, such as DNA, RNA, pigments
 1022 and polysaccharides, including GXM, as detailed in plain text.

1023



1024

1025 **Figure 8. Vaccination assays using *C. neoformans* EVs.**

1026 BALB/c mice of 6 weeks were firstly immunized with *C. neoformans* EVs via intraperitoneal
 1027 injection, after infected intranasally with 1×10^4 WT cells and the mice survival was finally
 1028 monitored. (A) In the first pilot experiment, mice (n = 4 per group) were immunized three times
 1029 with EV from WT, and *cap59 Δ* strains (EV-associated protein extract of 1 μ g/100 μ L or 10
 1030 μ g/100 μ L in PBS) and control mice were injected with 100 μ L PBS. Western Blot using mice
 1031 sera against fungal EV confirmed that all immunized mice produced antibodies against
 1032 vesicular components. (B) All EV-immunized mice survived longer than the non-immunized
 1033 ones, but the immunization with *cap59 Δ* EVs rendered the significantly prolonged mice
 1034 survival (*p=0.01). (C) For the second experiment, mice (n=10 per group) were immunized
 1035 five times uniquely with EV obtained from *cap59 Δ* strain (EV-associated protein extract of 10
 1036 μ g/100 μ L in PBS) and control mice were injected with 100 μ L PBS. Again, Western blot using
 1037 mice sera against fungal EV confirmed that all immunized mice produced antibodies against
 1038 EV components. (D) EV-immunized mice showed a higher significant prolonged survival
 1039 (*p=0.0006), compared to the unimmunized group. The comparison of the survival curves was
 1040 made by GraphPad Prism 8, using the Log-rank (Mantel-Cox) test.

1041

1042

1043

1044